BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. The Lancet Gastroenterology & Hepatology 2017;2:595-603. [DOI: 10.1016/s2468-1253(17)30106-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun X, Wang M, Zhang F, Kong X. Inhibition of NET-1 suppresses proliferation and promotes apoptosis of hepatocellular carcinoma cells by activating the PI3K/AKT signaling pathway. Exp Ther Med 2019;17:2334-40. [PMID: 30867719 DOI: 10.3892/etm.2019.7211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Moris D, Shaw BI, McElroy L, Barbas AS. Using Hepatocellular Carcinoma Tumor Burden Score to Stratify Prognosis after Liver Transplantation. Cancers (Basel) 2020;12:E3372. [PMID: 33202588 DOI: 10.3390/cancers12113372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 McVey JC, Sasaki K, Firl DJ. Risk assessment criteria in liver transplantation for hepatocellular carcinoma: proposal to improve transplant oncology. Hepat Oncol 2020;7:HEP26. [PMID: 32774836 DOI: 10.2217/hep-2020-0003] [Reference Citation Analysis]
5 Firl DJ, Sasaki K, Agopian VG, Gorgen A, Kimura S, Dumronggittigule W, McVey JC, Iesari S, Mennini G, Vitale A, Finkenstedt A, Onali S, Hoppe-Lotichius M, Vennarecci G, Manzia TM, Nicolini D, Avolio AW, Agnes S, Vivarelli M, Tisone G, Ettorre GM, Otto G, Tsochatzis E, Rossi M, Viveiros A, Cillo U, Markmann JF, Ikegami T, Kaido T, Lai Q, Sapisochin G, Lerut J, Aucejo FN; European Hepatocellular Cancer Liver Transplant Study Group. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology 2020;71:569-82. [PMID: 31243778 DOI: 10.1002/hep.30838] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
6 Seehofer D, Petrowsky H, Schneeberger S, Vibert E, Ricke J, Sapisochin G, Nault J, Berg T. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation—Adjusting the Odds? Transpl Int 2022;35:10333. [DOI: 10.3389/ti.2022.10333] [Reference Citation Analysis]
7 Huang Y, Chen H, Zeng Y, Liu Z, Ma H, Liu J. Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection. Front Oncol 2020;10:593741. [PMID: 33598425 DOI: 10.3389/fonc.2020.593741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Washburn K, Black S. Winners and Losers: Allocating Scare Resources for Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2017;24:3113-4. [PMID: 28687874 DOI: 10.1245/s10434-017-5990-4] [Reference Citation Analysis]
9 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
10 Al-Ameri AAM, Wei X, Liu P, Lin L, Shao Z, Xie H, Zhou L, Zheng S, Xu X. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study. Ann Transplant 2019;24:489-98. [PMID: 31427563 DOI: 10.12659/AOT.917296] [Reference Citation Analysis]
11 Mehta N, Yao FY. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken) 2019;13:20-5. [PMID: 31168361 DOI: 10.1002/cld.793] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
12 Kusakabe J, Firl DJ, Sasaki K. Toward the universal scoring system in treatment for patients with hepatocellular carcinoma. J Hepatol 2019;70:568-70. [PMID: 30554931 DOI: 10.1016/j.jhep.2018.10.024] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Zhang L, Yang Z, Zhang S, Zhou K, Zhang W, Ling S, Sun R, Tang H, Wen X, Feng X, Song P, Xu X, Xie H, Zheng S. Polyploidy Spectrum Correlates with Immunophenotype and Shapes Hepatocellular Carcinoma Recurrence Following Liver Transplantation. JIR 2022;Volume 15:217-33. [DOI: 10.2147/jir.s345681] [Reference Citation Analysis]
14 Salehi O, Vega EA, Kutlu OC, Lunsford K, Freeman R, Ladin K, Alarcon SV, Kazakova V, Conrad C. Poorly differentiated hepatocellular carcinoma: resection is equivalent to transplantation in patients with low liver fibrosis. HPB (Oxford) 2021:S1365-182X(21)01727-5. [PMID: 34969618 DOI: 10.1016/j.hpb.2021.12.001] [Reference Citation Analysis]
15 Vitale A, Scolari F, Bertacco A, Gringeri E, D'Amico F, Bassi D, D'Amico FE, Angeli P, Burra P, Lai Q, Cillo U. Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy? Cancers (Basel) 2021;13:2406. [PMID: 34067521 DOI: 10.3390/cancers13102406] [Reference Citation Analysis]
16 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Claasen MPAW, Ivanics T, Gravely A, Sapisochin G. Prognostic risk scores for liver transplantation: game changers or statistical artworks? Hepatobiliary Surg Nutr 2021;10:553-7. [PMID: 34430542 DOI: 10.21037/hbsn-21-258] [Reference Citation Analysis]
18 Firl DJ, Kimura S, McVey J, Hashimoto K, Yeh H, Miller CM, Markmann JF, Sasaki K, Aucejo FN. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy. Hepatology 2018;68:1448-58. [PMID: 29604231 DOI: 10.1002/hep.29907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
19 Hu X, Chen R, Wei Q, Xu X. The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We? Int J Biol Sci 2022;18:536-51. [PMID: 35002508 DOI: 10.7150/ijbs.64537] [Reference Citation Analysis]
20 Orci LA, Combescure C, Fink M, Oldani G, Compagnon P, Andres A, Berney T, Toso C. Predicting recurrence of hepatocellular carcinoma after liver transplantation using a novel model that incorporates tumor and donor-related factors. Transpl Int 2021. [PMID: 34784081 DOI: 10.1111/tri.14161] [Reference Citation Analysis]
21 Firl DJ, Sasaki K, Aucejo FN. Predicting Outcomes of Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018;154:1856-7. [PMID: 29621517 DOI: 10.1053/j.gastro.2017.11.296] [Reference Citation Analysis]
22 Wang J, Chen Z, Wang L, Feng S, Qiu Q, Chen D, Li N, Xiao Y. A new model based inflammatory index and tumor burden score (TBS) to predict the recurrence of hepatocellular carcinoma (HCC) after liver resection. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-12518-5] [Reference Citation Analysis]
23 Goldberg D, Mantero A, Newcomb C, Delgado C, Forde KA, Kaplan DE, John B, Nuchovich N, Dominguez B, Emanuel E, Reese PP. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021;74:1398-1406. [PMID: 33453328 DOI: 10.1016/j.jhep.2020.12.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Burra P, Zanetto A, Gambato M. Extending transplantation criteria for hepatocellular carcinoma. Lancet Gastroenterol Hepatol 2017;2:546-7. [PMID: 28546008 DOI: 10.1016/S2468-1253(17)30143-7] [Reference Citation Analysis]
25 Lang SA, Bednarsch J, Czigany Z, Joechle K, Kroh A, Amygdalos I, Strnad P, Bruns T, Heise D, Ulmer F, Neumann UP. Liver transplantation in malignant disease. World J Clin Oncol 2021; 12(8): 623-645 [PMID: 34513597 DOI: 10.5306/wjco.v12.i8.623] [Reference Citation Analysis]